See more : Shell plc (SHEL) Income Statement Analysis – Financial Results
Complete financial analysis of Tango Therapeutics, Inc. (TNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tango Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Orrstown Financial Services, Inc. (ORRF) Income Statement Analysis – Financial Results
- Fabryka Farb i Lakierów Sniezka SA (SKA.WA) Income Statement Analysis – Financial Results
- Joy City Property Limited (0207.HK) Income Statement Analysis – Financial Results
- The Sage Group plc (SGPYY) Income Statement Analysis – Financial Results
- Pason Systems Inc. (PSI.TO) Income Statement Analysis – Financial Results
Tango Therapeutics, Inc. (TNGX)
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Cost of Revenue | 115.20M | 4.03M | 1.97M | 1.63M | 32.27M |
| Gross Profit | -78.67M | 20.83M | 35.08M | 6.03M | -7.63M |
| Gross Profit Ratio | -215.38% | 83.80% | 94.69% | 78.77% | -30.93% |
| Research & Development | 115.20M | 105.91M | 77.64M | 49.99M | 32.27M |
| General & Administrative | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Other Expenses | 0.00 | 2.95M | 247.00K | 120.00K | 0.00 |
| Operating Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 7.15M |
| Cost & Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 39.43M |
| Interest Income | 6.62M | 1.46M | 495.00K | 108.00K | 684.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.42M | 4.03M | 1.97M | 1.63M | 643.00K |
| EBITDA | -111.76M | -109.46M | -57.29M | -51.48M | -14.52M |
| EBITDA Ratio | -305.96% | -446.79% | -157.09% | -672.44% | -58.90% |
| Operating Income | -114.17M | -111.07M | -58.19M | -52.20M | -15.16M |
| Operating Income Ratio | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Total Other Income/Expenses | 12.56M | 2.95M | 247.00K | 228.00K | 1.07M |
| Income Before Tax | -101.61M | -108.12M | -57.94M | -51.97M | -14.10M |
| Income Before Tax Ratio | -278.18% | -434.92% | -156.43% | -678.84% | -57.18% |
| Income Tax Expense | 134.00K | 54.00K | 292.00K | -108.00K | 0.00 |
| Net Income | -101.74M | -108.18M | -58.24M | -51.86M | -14.10M |
| Net Income Ratio | -278.54% | -435.14% | -157.21% | -677.43% | -57.18% |
| EPS | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Weighted Avg Shares Out | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
| Weighted Avg Shares Out (Dil) | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a...
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present...
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's...
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present...
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has...
Source: https://incomestatements.info
Category: Stock Reports